A Contemporary Pediatrics Peer Exchange panel reviews RSV risk, testing, maternal vaccination, and long-acting monoclonal antibodies, and where infants still slip through the cracks.
News|Videos|June 17, 2025
RX Review: Expanding options and addressing gaps in RSV prevention
Fact checked by: Morgan Ebert, Executive Editor, Victoria Johnson
In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.
Advertisement
Advertisement
As the field of RSV prevention continues to grow, pediatricians face both new opportunities and new challenges. From emerging immunoprophylaxis strategies to gaps in clinician and parent education, effective RSV management requires staying ahead of a changing landscape. In this second installment of the HCP Live Network RX Review roundtable on RSV, moderator Albert Rizzo, MD, chief medical officer of the American Lung Association, continues the conversation with leading pediatric experts Tina Tan, MD, and Joanne Nazif, MD.
Related to this article
Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.
With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.
Missed the AAP's new congenital measles guidance? This easy-to-read FAQ covers what pediatric clinicians need to know.
Johanna Chang, MD, offers guidance on vaccination, infection prophylaxis, and clinical warning signs in children receiving biologic therapies.
A GBD analysis of 204 countries estimated measles cases in children under 5 rose from 11.1 million in 2019 to 15.6 million in 2023.
Black race was the strongest predictor of T2-high inflammation in 451 children with severe asthma adjusted for social and environmental factors.
Advertisement
Advertisement